Cargando…

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?

Detalles Bibliográficos
Autores principales:	Merchan Muñoz, B., Subirá Pérez, D., Nuevo Lopez, M. I., Mora Argumanez, M., Pérez Alonso, R., Vazquez Ramo, A., Gil Perez, A., Guillen Garcia, H., Arbeteta Juanis, J., Santos Montero, A. B., Golbano Lopez, N., Herrero Lopez, S., Morales Sanz, M. D., De Miguel Llorente, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429355/ http://dx.doi.org/10.1097/01.HS9.0000851348.60558.49

Ejemplares similares

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

PB2270: PROGNOSTIC VALUE OF INTERIM POSITRON EMISSION TOMOGRAPHY IN HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA
por: Argumánez, Marta Mora, et al.
Publicado: (2023)

PB2628: EXPERIENCE AT THE GUADALAJARA UNIVERSITY HOSPITAL (SPAIN) IN FETAL AND NEONATAL ALLOINMUNE THROMBOCYTOPENIA (FNAIT) DURING EIGHT YEARS.
por: López, María Irene Nuevo, et al.
Publicado: (2023)

PB2491: LANGERHANS CELL HISTIOCYTOSIS (LCH) IN THE MAXILLOFACIAL AREA IN ADULT. COMPLETE REMISSION WITH CLADRIBINE. CASE REPORT AND REVIEW.
por: De Miguel Llorente, Dunia, et al.
Publicado: (2023)

PB2703: ISA-KD IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL LIFE.
por: Llorente, Dunia De Miguel, et al.
Publicado: (2023)

PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)
por: Holstein, Sarah A., et al.
Publicado: (2023)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB2572: LYMPHOPENIA RATE; A FREE EPIDEMIOLOGICAL BIOMARKER FOR COVID-19 PANDEMIC
por: Helali, Intissar, et al.
Publicado: (2023)

PReS-FINAL-2129: Whole-body versus localized magnetic resonance imaging in the assessment of juvenile dermatomyositis
por: Madeo, A, et al.
Publicado: (2013)

PB2341: EARLY MORTALITY VARIABLES IN PATIENTS OLDER THAN 75 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

PB2165: BIOINFORMATIC TOOL FOR IMMUNOMODULATING THE ONCOGENIC TRANSCRIPTOME OF ABC-DLBCLS
por: Rodríguez, M., et al.
Publicado: (2022)

2129. Utilization of Post-Discharge Antibiotics in Spinal Fusion in a Nationwide Cohort of Commercially Insured Individuals
por: Warren, David K, et al.
Publicado: (2018)

PB2126: RETROSPECTIVE REAL LIFE STUDY OF MULTIPLE MYELOMA STATUS AT DEATH.
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

2129. When Is Methicillin-resistant Staphylococcus aureus not Methicillin-resistant Staphylococcus aureus?
por: Gitman, Melissa R, et al.
Publicado: (2019)

PB2047: MOLECULAR DIAGNOSIS OF CONGENITAL ERYTHROCYTOSIS IN A SINGLE HOSPITAL CENTER.
por: Castilla Garcia, L., et al.
Publicado: (2022)

PB2384: EVALUATION OF NEW MACHINE LEARNING SYSTEMS FOR PROGNOSTICATION BASED ON GENE EXPRESSION SIGNATURES IN MANTLE CELL AND PERIPHERAL T CELL LYMPHOMAS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

PB2088: IMMUNE PROFILE OF PATIENTS WITH FOLLICULAR LYMPHOMA ASSESSED BY FLOW CYTOMETRY IN PERIPHERAL BLOOD: CHARACTERISTICS AT DIAGNOSIS AND AT RELAPSE OF THE DISEASE
por: Rivero Arango, A., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
por: Muñiz, Ó., et al.
Publicado: (2022)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
por: Hamadani, M., et al.
Publicado: (2022)

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.
por: Martínez, Javier Alberto Rojas, et al.
Publicado: (2023)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

PB2215: HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2268: IMPACT OF HEMATOLOGICAL DISORDERS ON MORTALITY AND SERIOUS OUTCOMES IN SARS-COV-2 INFECTION: A MULTICENTER COHORT STUDY
por: Hernandez Perez, A. P., et al.
Publicado: (2022)

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
por: Pérez-Pinilla, Belén, et al.
Publicado: (2023)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

2129. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
por: Hackel, Meredith, et al.
Publicado: (2023)

PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA
por: Zamanillo, I., et al.
Publicado: (2022)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

PB2590: BREAKTHROUGH INVASIVE FUNGAL INFECTION CAUSED BY SCEDOSPORIUM APIOSPERMUM IN PEDIATRIC PATIENT WITH ACUTE MYELOID LEUKEMIA: DIAGNOSTIC, CLINICAL COURSE AND TREATMENT
por: Raya, María Pérez, et al.
Publicado: (2023)

PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
por: Buquicchio, Caterina, et al.
Publicado: (2023)

PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Lakhwani, Sunil Lakhwani, et al.
Publicado: (2023)

Graves’ Disease in the Young: Could We Change the Weather?
por: Rodien, Patrice
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dqsqsh7935fagsj9sc53cm51hq